Our data revealed that the active lactam steroid alkylator ASA-B exhibited a significantly higher anticancer activity in the BRCA1-null ovarian cancer cell line UWB1.289 than in the respective BRCA1 wild-type UWB1.289 + BRCA1 ovarian cancer cell line. Here, BRCA1 is linked to ovarian carcinoma.